

Crefmirlimab Biosimilar - Research Grade

Product Code: ICH5453

More Information

Species Reactivity: Human

Target: CD8A[Human]

Concentration: 5mg/ml

Isotype: (scFv - kappa - heavy) -h- CH3

Host: CHO Cells

product name H2: Crefmirlimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P01732

Shipping Conditions: Blue ice

background: CD8A is a co-receptor that defines cytotoxic T lymphocytes and stabilizes MHC class I recognition, making it a key marker in T-cell-immunology and immuno-oncology research. This reagent is an unconjugated, non-therapeutic analog of crefmirlimab, supplied here in a recombinant scFv-based (kappa-heavy CH3) minibody format for research use only (RUO). It is formulated low in endotoxin to in vivo standards and produced in scalable milligram-to-gram quantities for high-throughput laboratories. It supports functional and binding assays, CD8 T-cell detection and tracking studies, in vitro screening and preclinical immune-monitoring models, with dependable consistency.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks